GeneSpector Innovations presents a novel, patent-protected treatment method for SARS-CoV-2 infections utilizing heme arginate, which is a known compound currently used in treatment of acute attacks of hepatic porphyria.

In vitro studies using human cells infected with SARS-CoV-2 have shown that application of heme arginate reduces viral replication in infected cells 1,000-times. Additionally, presence of the compound increases survival rate of infected cells by 80 %, thus significantly reducing tissue damage.

Presented results suggest a significant potential of heme arginate in treatment of COVID-19 by decreasing patient’s overall viral load and by protecting their infected tissues from damage. Therapy can be applied both before and after manifestation of the symptoms to reduce severity or to completely prevent development of the infectious disease.